分泌组传递ASCs的保护效应:出血性休克后的治疗潜力?
该研究在大鼠出血性创伤性休克(HTS)模型中,于限制性再灌注开始20分钟后静脉给予2×10^6个脂肪来源干细胞(ASC组)、相当于2×10^6个ASCs/24小时产生的分泌组(ASC-分泌组组)或溶媒(溶媒组),观察28天生存。与溶媒组相比,48小时IL-6在ASC组抑制80%(P<0.001)、在ASC-分泌组组抑制59%(P<0.01);24小时血浆丙氨酸氨基转移酶在ASC组和ASC-分泌组组均改善36%(P<0.001);对肾功能和/或一般细胞损伤标志物无影响;28天死亡率溶媒组18%,ASC组12%(P=0.08)、ASC-分泌组组未见该效应。作者认为无细胞分泌组具有抗炎和肝脏保护作用,且因制备、储存、可获得性和应用更便利,在急性出血性休克早期治疗潜力更好。
要点
- 大鼠HTS复苏模型中,限制性再灌注开始20分钟时静脉给予分泌组(相当于2×10^6个ASCs/24小时产量),48小时IL-6较溶媒组抑制59%(P<0.01)。
- 同一时间点静脉给予2×10^6个ASC,48小时IL-6较溶媒组抑制80%(P<0.001)。
- 24小时血浆丙氨酸氨基转移酶在ASC组和ASC-分泌组组均较溶媒组改善36%(P<0.001),对肾功能和/或一般细胞损伤标志物无影响。
- 28天死亡率溶媒组18%,ASC组12%(P=0.08),ASC-分泌组组未见该效应。
- 作者认为无细胞分泌组制备、储存、可获得性和应用更便利,在急性出血性休克早期治疗潜力更好。
适用人群与场景
- 大鼠出血性创伤性休克(HTS)模型,接受模拟院前限制性再灌注后充分再灌注的复苏方案。
处置流程与药物剂量
- 限制性再灌注开始20分钟时静脉团注2×10^6个ASC(ASC组)或相当于2×10^6个ASCs/24小时产生的分泌组(ASC-分泌组组);溶媒组给予溶媒。
- 所有大鼠观察28天生存。
研究设计与关键结果
- 研究类型为大鼠在体实验;与溶媒组相比,48小时HTS诱导的IL-6在ASC组抑制80%(P<0.001)、在ASC-分泌组组抑制59%(P<0.01)。
- 24小时血浆丙氨酸氨基转移酶在ASC组和ASC-分泌组组均较溶媒组改善36%(P<0.001);对肾功能和/或一般细胞损伤标志物无影响。
- 28天死亡率溶媒组18%,ASC组12%(P=0.08),ASC-分泌组组未见该效应。
证据类型、等级与局限
- 证据类型:动物实验(大鼠HTS模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,无细胞分泌组在急性出血性休克早期具有更好的治疗潜力,理由是其制备、储存、可获得性和应用较干细胞更便利。
- 原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We tested whether resuscitation supplemented with rat adipose-derived stem cells (ASCs) or secretome (conditioned media) of ASCs can ameliorate inflammation, cell/organ injury, and/or improve outcome after hemorrhagic traumatic shock (HTS).
INTERVENTIONS: Rats were subjected to HTS and a resuscitation protocol that mimics prehospital restrictive reperfusion followed by an adequate reperfusion phase. Twenty minutes into the restrictive reperfusion, animals received an intravenous bolus of 2 × 10 cells (ASC group) or the secretome produced by 2 × 10 ASCs/24 h (ASC-Secretome group). Controls received the vehicle (Vehicle group). All rats were observed for 28-day survival.
MEASUREMENTS AND MAIN RESULTS: HTS-induced inflammation represented by IL-6 was inhibited in the ASC (80%, P < 0.001) and in ASC-Secretome (59%, P < 0.01) group at 48 h compared with Vehicle group. At 24 h, HTS-induced liver injury reflected in plasma alanine aminotransferase was ameliorated by 36% (P < 0.001) in both the ASC and ASC-Secretome groups when compared with the Vehicle. There was no effect on kidney function and/or general cell injury markers. HTS induced a moderate 28-day mortality (18%) that was prevented (P = 0.08) in the ASC but not in the ASC-Secretome group (12%).
CONCLUSIONS: Our data suggest that the ASC-secretome supplemented resuscitation following HTS, in the absence of the stem cells, exerts anti-inflammatory and liver protective effects. Given its ease of preparation, storage, availability, and application (in contrast to the stem cells) we believe that the cell-free secretome has a better therapeutic potential in the early phase of an acute hemorrhagic shock scenario.
参考来源
- Ashmwe M, Penzenstadler C, Bahrami A, et al. Secretome Conveys the Protective Effects of ASCs: Therapeutic Potential Following Hemorrhagic Shock? Shock. 2018. PMID: 29112105. doi:10.1097/SHK.0000000000001047
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。